AstraZeneca PLC
- AZN
- NYSE
- Drug manufacturers
- Prescription Medicines (Oncology/Respiratory)
- Biopharmaceuticals
$165.41
Today −0.76%Quote Oct 16, 2026, 08:00 PM UTC
−0.44%over the last month
Max drawdown −7.5%From 1-month high −1.8%3 months +0.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$256.53B
Quote Oct 16
Next earnings
Oct 30
Expected, not confirmed
Analyst target
$186.67
+12.9% from here
Floor
$164.91
0.3% below price
Where the price sits
41 analysts
Analyst range, low to high
$158.00$216.00
- Price $165.41
- Resistance $168.57–$170.27
- Consensus $186.67
The price is just above its floor and right under resistance. Analysts' average target sits about 13% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AZNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2023 revenue $16.98B
- Total Oncology$4.38B25.8%
- Farxiga$1.50B8.9%
- Tagrisso$1.49B8.8%
- BioPharmaceuticals: total Respiratory & Immunology$1.48B8.7%
- Imfinzi$1.08B6.3%
- Soliris$814.0M4.8%
- Lynparza$717.0M4.2%
- Ultomiris$713.0M4.2%
- Calquence$653.0M3.8%
- Symbicort$600.0M3.5%
- Fasenra$406.0M2.4%
- Brilinta$331.0M1.9%
- Other$2.81B16.5%
Industry
Drug manufacturers
Employees
96,100
Founded
1992